Evidence map›Paper›PMID 41450449›Full record

ArticleJPRAS open2026

A 10-year recurrence-free natural course of high-risk stage II cutaneous melanoma: A case report.

Benedikt Bauer, Marcel Mayrhofer, Maximilian Zarfl, Lars-Peter Kamolz, Hanna Luze, Sebastian Philipp Nischwitz

Abstract readCase Reports
In one paragraph

Article in JPRAS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Benedikt BauerDivision of Plastic, Reconstructive, and Aesthetic Surgery, Department of Surgery, Medical University Graz.
Marcel MayrhoferDepartment of Dermatology, Medical University Graz, Graz, Austria.
Maximilian ZarflResearch Unit for Responsible Aesthetics, Division of Plastic, Reconstructive, and Aesthetic Surgery, Department of Surgery, Medical University of Graz, Graz, Austria.
Lars-Peter KamolzDivision of Plastic, Reconstructive, and Aesthetic Surgery, Department of Surgery, Medical University Graz.
Hanna LuzeResearch Unit for Responsible Aesthetics, Division of Plastic, Reconstructive, and Aesthetic Surgery, Department of Surgery, Medical University of Graz, Graz, Austria.
Sebastian Philipp NischwitzResearch Unit for Responsible Aesthetics, Division of Plastic, Reconstructive, and Aesthetic Surgery, Department of Surgery, Medical University of Graz, Graz, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: pT4b melanoma of the skin, especially the nodular subtype with present ulceration, typically entails a poor prognosis with high risk for metastatic spread. The accuracy of classic risk prediction models lacks at times. When situated in the face, these malignancies can pose a specific challenge to reconstructive surgeons. Profound fears of cancer treatment further complicate the management of these cases. Case presentation: We present a case of facial reconstruction in a 58-year-old female patient with a high-risk stage II melanoma with recurrence-free survival (RFS) despite an almost 10-year delay of surgical treatment due to existential fears. Conclusions: The presented case provides several key takeaways. First, from a dermatological standpoint, clinicians must expect the unexpected and should look for explanations. Second, from a reconstructive view, complex cases are rarely linear-staged revisions, and setbacks are integral to surgical success. Finally, from a human perspective, sincere empathy, and emotional intelligence are indispensable.

Indexed as

Disease-free survivalEmpathyFacial reconstructionHigh-risk melanomaMetastasisReconstructive surgerySurgical oncology

Identifiers

PMID41450449
PMCPMC12731293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.